Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients
Launched by NATIONAL CANCER CENTER, KOREA · Jan 13, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to locate sentinel lymph nodes in women who have locally recurrent breast cancer. Sentinel lymph nodes are the first places cancer might spread, and checking them helps doctors understand the cancer's stage and plan treatment. The study is testing a technique that combines traditional imaging methods with a special dye called indocyanine green (ICG) that helps highlight these nodes during surgery. This new approach aims to improve the detection rate of these lymph nodes and reduce the need for more invasive surgeries like axillary lymph node dissection, which can have more complications.
To participate in this trial, women must be at least 18 years old and have experienced a recurrence of breast cancer in the same area after having undergone prior surgery on the same side. They should also be in good enough health to engage in the study. Participants can expect to undergo a procedure that uses these advanced imaging techniques to help locate their sentinel lymph nodes more effectively. It's important to note that this study is currently recruiting eligible participants, and all volunteers must provide their consent to take part.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with ipsilateral locally recurrent breast cancer who previously underwent ipsilateral axillary surgery.
- • Female patients aged 18 years or older.
- • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- • Patients who voluntarily decide to participate in the study and provide written informed consent.
- Exclusion Criteria:
- • Patients with distant metastases.
- • Patients who previously underwent ipsilateral mastectomy.
- • Pregnant or breastfeeding women.
- • Patients with a general condition that impairs the ability to understand or provide informed consent.
About National Cancer Center, Korea
The National Cancer Center Korea (NCC Korea) is a leading institution dedicated to cancer research, prevention, diagnosis, and treatment. As a prominent clinical trial sponsor, NCC Korea focuses on advancing innovative therapies and improving patient outcomes through rigorous scientific investigation and collaborative efforts. With a commitment to enhancing cancer care, the center conducts a wide range of clinical trials, fostering partnerships with academic institutions, healthcare providers, and industry stakeholders to translate research findings into effective clinical applications. Through its comprehensive approach, NCC Korea aims to contribute significantly to the global fight against cancer, ensuring that advancements in treatment are accessible to patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Goyang Si, Gyeonggi Do, Korea, Republic Of
Patients applied
Trial Officials
SEEYOUN LEE
Principal Investigator
National Cancer Center, Korea
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported